AAVXF:OTC-ABIVAX Société Anonyme (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 7.37

Change

0.00 (0.00)%

Market Cap

USD 0.47B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-11 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
ARGNF argenx SE

N/A

USD 39.01B
UCBJF UCB SA

N/A

USD 37.94B
UCBJY UCB SA ADR

N/A

USD 37.34B
GNMSF Genmab A/S

N/A

USD 13.64B
WXIBF WuXi Biologics

N/A

USD 8.99B
WXXWY WuXi Biologics (Cayman) Inc

N/A

USD 8.93B
IVBIY IVBIY

N/A

USD 7.80B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 7.48B
ZLDPF Zealand Pharma A/S

N/A

USD 7.14B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 6.89B

ETFs Containing AAVXF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -29.81% 47% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.81% 47% F 32% F
Trailing 5 Years  
Capital Gain -69.51% 57% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -69.51% 55% F 29% F
Average Annual (5 Year Horizon)  
Capital Gain 4.24% 49% F 45% F
Dividend Return 4.24% 50% F 41% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 57.54% 63% D 47% F
Risk Adjusted Return 7.36% 53% F 40% F
Market Capitalization 0.47B 87% B+ 68% D+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector